1. EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes
   Taylor Harding et al, 2018, Oncotarget CrossRef
2. Epigenetics of Triple-Negative Breast Cancer via Natural Compounds
   Mohammed Kaleem et al, 2022, Current Medicinal Chemistry CrossRef
3. Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells
   Annalisa Romanelli et al, 2020, ACS Medicinal Chemistry Letters CrossRef
4. TXNIP mediated by EZH2 regulated osteogenic differentiation in hBmscs and MC3T3-E1 cells through the modulation of oxidative stress and PI3K/AKT/Nrf2 pathway
   Weibo Zhou et al, 2024, Connective Tissue Research CrossRef
5. Inflammatory Immune-Associated eRNA: Mechanisms, Functions and Therapeutic Prospects
   Lilin Wan et al, 2022, Frontiers in Immunology CrossRef
6. The role of H3K27me3 methylation in cancer development
   Longjiang Di et al, 2024, Genome Instability & Disease CrossRef
7. Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension
   Malik Bisserier et al, 2021, Circulation CrossRef